<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408914</url>
  </required_header>
  <id_info>
    <org_study_id>11-0050</org_study_id>
    <secondary_id>5U01AI091429-03</secondary_id>
    <nct_id>NCT01408914</nct_id>
  </id_info>
  <brief_title>Trial of High-Dose Rifampin in Patients With TB</brief_title>
  <acronym>HIRIF</acronym>
  <official_title>Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard University Faculty of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Socios en Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard University Faculty of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential of high doses of rifampin (RIF) to
      shorten treatment for tuberculosis (TB) without causing more adverse events. The hypotheses
      are that higher doses of RIF will result in higher blood concentrations of RIF; higher blood
      concentrations will result in tuberculosis bugs being killed more quickly; and, both of these
      will happen without more adverse events. Patients with active, infectious, drug-susceptible
      TB who agree to participate will be randomly assigned to 1 of 3 doses of RIF. All patients
      will also receive standard doses of regular (3) companion drugs for 2 months of daily,
      supervised therapy. The study will assess the following among the 3 study arms (oral doses of
      RIF 10, 15 &amp; 20 mg/kg/day) during the initial 8 weeks of treatment: 1) the amount of RIF in
      the blood after at least 14 days of treatment; 2) the difference in the number of
      tuberculosis bugs killed; 3) the frequency of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, multi-site, dose-ranging trial comparing 3 doses of RIF in a multidrug
      regimen for treatment of smear-positive, pulmonary TB. The intervention phase of this
      prospective, randomized, double-blinded trial will last 8 weeks, the duration of the standard
      &quot;intensive&quot; phase for short-course chemotherapy for TB. During that time, subjects will
      receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20
      mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used
      in treatment. Subjects will also be randomized to receive one of the following weight-based
      doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day
      (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard
      dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo
      will be used to control only the additional RIF capsules provided in the intervention arms.
      Subjects, clinicians, and laboratory staff will be blinded to study arm. All patients in the
      same weight band will receive the same total number of tablets (fixed-dose combination plus
      RIF and/or placebo). Blinding is essential to reduce the probability of biased reporting of
      adverse events.

      After randomization, other covariates that may result in heterogeneity within strata (e.g.,
      presence of cavitation, HIV serostatus), will be adjusted for in analyses. It is important to
      maintain the ability to measure the effect (if any) of these potential characteristics on
      treatment outcome. If we were to stratify on these characteristics, we could not estimate
      their confounding (or interaction) effect. All doses will be delivered orally and fully
      supervised. All patients will receive weight-based doses of fixed-dose combinations according
      to package inserts. This will be supplemented by active RIF capsules or placebos, or both,
      according to weight and treatment arm. They will also all receive 50 mg of pyridoxine to
      prevent peripheral neuropathy, a common side effect of INH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady State Pharmacokinetic Exposure of RIF</measure>
    <time_frame>At any time during the intensive phase of treatment, after steady state has been reached (at a minimum, after 14 days of daily RIF delivery)</time_frame>
    <description>The endpoint is the (dimensionless) ratio of AUC0-6 mcg/ml*h to MIC99.9 mcg/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum Culture Sterilization During the Initial 8 Weeks of Treatment</measure>
    <time_frame>Until 8 weeks of treatment are completed</time_frame>
    <description>Number of participants that are sputum culture (in LJ) negative for TB at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rifampin-related Grade 2 or Higher Adverse Events</measure>
    <time_frame>Throughout the 12 weeks post treatment initiation</time_frame>
    <description>Number of participants experiencing at least one rifampin-related grade 2 or higher adverse events during the initial 8 weeks of treatment and up to four weeks after.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>RIF 600</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RIF 900</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RIF 1200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher-Dose Rifampin</intervention_name>
    <description>The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.</description>
    <arm_group_label>RIF 900</arm_group_label>
    <arm_group_label>RIF 1200</arm_group_label>
    <other_name>rifadin, rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed pulmonary TB with acid-fast bacilli (&gt;=2+) in a stained sputum smear,
             ultimately confirmed by culture.

          -  Susceptibility of isolate to INH and RIF by HAIN test.

          -  Willingness to undergo HIV testing according to the National Health Guidelines for TB
             control in Peru. The study will also consider patients who have had negative HIV
             serostatus documented within six months prior to enrollment or if verifiable positive
             serostatus was documented using a validated test any time previously.

          -  Age &gt;/= 18 years and &lt;61 years.

          -  Signed informed consent.

          -  Negative serum pregnancy test (women of childbearing potential).

          -  Women with child-bearing potential must agree to practice a double-barrier method of
             birth control during treatment. Adequate contraceptives (condoms and spermicide) will
             be provided by the study to avoid pregnancy among female subjects.

          -  Karnofsky score of at least 50 (requires considerable assistance and frequent medical
             care).

          -  Intends to remain in jurisdiction of health center during study and follow up.

        Exclusion Criteria:

          -  Body weight &lt;30 kg.

          -  Prior treatment with multidrug anti-TB therapy for more than one month.

          -  Resistance on HAIN to INH and/or RIF. These patients will be treated according to
             local programmatic guidelines.

          -  Central nervous system or miliary TB.

          -  Clinical or radiological signs suggestive of pericardial or pleural involvement.

          -  Presence of significant hemoptysis. Patients who cough up frank blood (more than
             blood-streaked sputum) will not be eligible for enrollment.

          -  Known intolerance to any of the study drugs; use of concomitant drugs that interfere
             with the pharmacokinetics of anti-TB drugs; use of concomitant hepatotoxic drugs
             (other than companion study drugs) for which potential drug interactions or
             synergistic toxicity are known: boosted protease inhibitors, non-nucleoside reverse
             transcriptase inhibitors, azole antifungals and statins; use of antibiotics that are
             contraindicated during the study's TB therapy; current daily use of acetaminophen or
             paracetamol for two weeks or more.

          -  History of liver disease.

          -  Uncontrolled condition that might interfere with drug absorption, distribution,
             metabolism or excretion (i.e. chronic gastrointestinal disease, renal insufficiency
             defined by creatinine clearance &lt;60mL/min).

          -  Uncontrolled diabetes mellitus (HbA1c&gt;7.5%).

          -  Refusal to be tested for HIV infection; HIV infection with contraindication for
             treatment with efavirenz (including resistance).

          -  Pulmonary silicosis.

          -  Breastfeeding.

          -  Rifampin contraindications such as hypersensitivity or jaundice.

          -  Likely difficulty adhering to the protocol, as assessed by the investigator.

          -  Laboratory results in the 14 days preceding enrollment showing:

               1. Serum amino alanine transferase (ALT) &gt;2 times upper limit of normal

               2. Serum total bilirubin concentration &gt;2.5 times upper limit of normal

               3. Serum creatinine concentration &gt; 2 times upper limit of normal and/or creatinine
                  clearance &lt;60 mL/min

               4. Hemoglobin concentration &lt; 7.0 g/dL

               5. Platelet count &lt; 150,000/mm3

               6. White blood count &lt;4500 cells/μL.

          -  Having a serological test positive for HBVsAg (hepatitis B virus surface antigen) or
             for HCVAb (hepatitis C virus antibody)test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole D Mitnick, Sc.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geraint Davies, B.M., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Socios En Salud Sucursal Perú</name>
      <address>
        <city>Lima 6</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Clinical Sciences at University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's University of London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <reference>
    <citation>Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 Aug 27;16(1):453. doi: 10.1186/s12879-016-1790-x.</citation>
    <PMID>27567500</PMID>
  </reference>
  <results_reference>
    <citation>Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00038-17. doi: 10.1128/AAC.00038-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.</citation>
    <PMID>28559269</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <results_first_submitted>May 3, 2017</results_first_submitted>
  <results_first_submitted_qc>June 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard University Faculty of Medicine</investigator_affiliation>
    <investigator_full_name>Carole Mitnick</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was done through routine passive case detection in operation at ambulatory facilities in the Peruvian public health system (DISA IV-Lima Este and DISA V- Lima Ciudad).</recruitment_details>
      <pre_assignment_details>180 participants were randomized in a 1:1:1 allocation to the 10, 15, and 20 mg/kg treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>10 mg/kg</title>
          <description>10 mg/kg RIF</description>
        </group>
        <group group_id="P2">
          <title>15 mg/kg</title>
          <description>15 mg/kg RIF</description>
        </group>
        <group group_id="P3">
          <title>20 mg/kg</title>
          <description>20 mg/kg RIF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Could not complete tx in protocol period</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of study jurisdiction</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Late exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in local TB/HIV norms</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mg/kg</title>
          <description>10 mg/kg RIF</description>
        </group>
        <group group_id="B2">
          <title>15 mg/kg</title>
          <description>15 mg/kg RIF</description>
        </group>
        <group group_id="B3">
          <title>20 mg/kg</title>
          <description>20 mg/kg RIF</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="21" upper_limit="37"/>
                    <measurement group_id="B2" value="25" lower_limit="20" upper_limit="35"/>
                    <measurement group_id="B3" value="27" lower_limit="22" upper_limit="37"/>
                    <measurement group_id="B4" value="25" lower_limit="21" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady State Pharmacokinetic Exposure of RIF</title>
        <description>The endpoint is the (dimensionless) ratio of AUC0-6 mcg/ml*h to MIC99.9 mcg/ml</description>
        <time_frame>At any time during the intensive phase of treatment, after steady state has been reached (at a minimum, after 14 days of daily RIF delivery)</time_frame>
        <population>Analysis was completed in 168 participants evaluable for pharmacokinetics, as samples were unable to be collected in 12 study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg/kg</title>
            <description>10 mg/kg RIF</description>
          </group>
          <group group_id="O2">
            <title>15 mg/kg</title>
            <description>15 mg/kg RIF</description>
          </group>
          <group group_id="O3">
            <title>20 mg/kg</title>
            <description>20 mg/kg RIF</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Pharmacokinetic Exposure of RIF</title>
          <description>The endpoint is the (dimensionless) ratio of AUC0-6 mcg/ml*h to MIC99.9 mcg/ml</description>
          <population>Analysis was completed in 168 participants evaluable for pharmacokinetics, as samples were unable to be collected in 12 study participants.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6988" lower_limit="59.1233" upper_limit="197.5544"/>
                    <measurement group_id="O2" value="201.9725" lower_limit="144.1413" upper_limit="460.2869"/>
                    <measurement group_id="O3" value="284.4278" lower_limit="175.2923" upper_limit="399.2127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Culture Sterilization During the Initial 8 Weeks of Treatment</title>
        <description>Number of participants that are sputum culture (in LJ) negative for TB at 8 weeks</description>
        <time_frame>Until 8 weeks of treatment are completed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 mg/kg</title>
            <description>10 mg/kg RIF</description>
          </group>
          <group group_id="O2">
            <title>15 mg/kg</title>
            <description>15 mg/kg RIF</description>
          </group>
          <group group_id="O3">
            <title>20 mg/kg</title>
            <description>20 mg/kg RIF</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Culture Sterilization During the Initial 8 Weeks of Treatment</title>
          <description>Number of participants that are sputum culture (in LJ) negative for TB at 8 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Rifampin-related Grade 2 or Higher Adverse Events</title>
        <description>Number of participants experiencing at least one rifampin-related grade 2 or higher adverse events during the initial 8 weeks of treatment and up to four weeks after.</description>
        <time_frame>Throughout the 12 weeks post treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 mg/kg</title>
            <description>10 mg/kg RIF</description>
          </group>
          <group group_id="O2">
            <title>15 mg/kg</title>
            <description>15 mg/kg RIF</description>
          </group>
          <group group_id="O3">
            <title>20 mg/kg</title>
            <description>20 mg/kg RIF</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Rifampin-related Grade 2 or Higher Adverse Events</title>
          <description>Number of participants experiencing at least one rifampin-related grade 2 or higher adverse events during the initial 8 weeks of treatment and up to four weeks after.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10 mg/kg</title>
          <description>10 mg/kg RIF</description>
        </group>
        <group group_id="E2">
          <title>15 mg/kg</title>
          <description>15 mg/kg RIF</description>
        </group>
        <group group_id="E3">
          <title>20 mg/kg</title>
          <description>20 mg/kg RIF</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>OB-GYN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carole Mitnick</name_or_title>
      <organization>Harvard Medical School</organization>
      <phone>617-432-6018</phone>
      <email>Carole_Mitnick@hms.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

